MAY 04, 2020 8:30 AM PDT

GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work

SPONSORED BY: Sino Biological

GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-CoV-2 (COVID-19) bioreagent research products.

Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies.  Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has the world’s largest selection of coronavirus research-grade products. GeoVax is at the forefront of development for a COVID-19 vaccine and its use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.

Commenting on the exclusive partnership, David A. Dodd, GeoVax Chairman & CEO stated, “We are delighted to establish this collaboration with Sino Biological related to our COVID-19 vaccine development program. Sino Biological is recognized as the research reagent industry leader in developing and providing COVID-19 bioreagent research products, as well as a leader throughout the bioreagent research industry. We look forward to further expansion of our relationship with Sino Biological, including our agreement related to research-use-only (RUO) reagents.

“GeoVax’s unique VLP-generation technology is exciting, and its commitment to the development of a vaccine for COVID-19 is inspiring. We at Sino Biological are honored to be the exclusive provider of COVID-19-related research reagents to assist their vaccine development efforts.”, commented Rob Burgess, Ph.D., Chief Business Officer for Sino Biological.

Contacts: 
GeoVax Labs, Inc.
investor@geovax.com
+1-678-384-7220

Sino Biological, Inc.
bd@sinobiological.com
+1-215-583-7898

About the Sponsor
  • Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant antigen production and antibody development, and also offers a variety of customized services, mainly focusing on recombinant production of antigens and antibodies. Sino Biological is dedicated to virology and infectious disease research. Its newly launched ProVir(TM) collection is the world’s largest viral antigen bank.
You May Also Like
AUG 14, 2020
Microbiology
Seasonal Flu Vaccine Immunity Probably Wears Off
AUG 14, 2020
Seasonal Flu Vaccine Immunity Probably Wears Off
From year to year, the influenza virus mutates and swaps genes with other flu viruses, and we need a new vaccine. But th ...
AUG 19, 2020
Immunology
Cancer Mutation Improves Chemo Drug Performance
AUG 19, 2020
Cancer Mutation Improves Chemo Drug Performance
When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcom ...
AUG 21, 2020
Immunology
Cancer Feels the STING
AUG 21, 2020
Cancer Feels the STING
Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon gen ...
SEP 17, 2020
Immunology
COVID Vaccine Works in Macaques - What about in Humans?
SEP 17, 2020
COVID Vaccine Works in Macaques - What about in Humans?
Pharmaceutical giant Pfizer, in partnership with BioNTech has reported that one of its lead vaccine candidates has shown ...
NOV 04, 2020
Coronavirus
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
NOV 04, 2020
Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients
COVID-19, the illness caused by the pandemic virus SARS-CoV-2, is known to cause blood clots all over the body in some p ...
NOV 17, 2020
Immunology
6 Injections a Year Prevent HIV Infections
NOV 17, 2020
6 Injections a Year Prevent HIV Infections
Last year, around 1.7 million people became infected with HIV, with around half of these being women. Encouraging result ...
Loading Comments...